Etesevimab is a humanized anti-SARS-CoV-2 neutralizing monoclonal antibody, co-developed by Eli Lilly and Company and Junshi Biosciences. It binds to the spike protein of SARS-CoV-2, blocking viral attachment and entry into host cells. It is authorized for use in combination with bamlanivimab under Emergency Use Authorization (EUA).

Main Indications
Treatment of mild to moderate COVID-19 in non-hospitalized patients at high risk for progression to severe disease, hospitalization, or death.
Post-exposure prophylaxis for COVID-19 in individuals exposed to the virus who are at high risk of severe illness.

Common Side Effects
Common mild adverse reactions: Nausea, dizziness, rash, pruritus, and infusion site reactions.
Severe but uncommon risks: Hypersensitivity reactions, anaphylaxis, and infusion-related reactions.

Approval Status in China
Etesevimab (LY-CoV016/JS016) has not received formal marketing approval in China; it was authorized for emergency use in combination with bamlanivimab in some regions but is not currently approved for general clinical use.

Buy Etesevimab Injection online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.